This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zanger, D. Articles by Cannon, R. O. Search for Related Content PubMed PubMed Citation Articles by Zanger, D. Articles by Cannon, R. O., III

Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management

^a Cardiology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
^b Office of Biostatistics Research, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
^c Immunopathology Section, National Institute of Dental and Craniofacial Research, Bethesda, Maryland, USA
^d Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA

View larger version (17K): [in a new window]   Figure 1 Serum levels of the cell adhesion molecules E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are shown for the 10 study participants during placebo and hormone therapy (HT) treatment periods of the study. CEE = conjugated equine estrogens; MPA = medroxyprogesterone acetate.

View larger version (16K): [in a new window]   Figure 2 Matrix metalloproteinase-9 (MMP-9) serum levels by ELISA are shown for the 10 study participants identified by letters A through J (the order of entry into the study) and during placebo and hormone therapy treatment phases of the study. CEE = conjugated equine estrogens; MPA = medroxyprogesterone acetate.

View larger version (53K): [in a new window]   Figure 3 Panel A: Zymography of paired serum samples from the 10 study participants with coronary artery disease shows digestion of gelatin at the 92 kDa band, indicative of the proenzyme form of MMP-9, during placebo (–) and hormone therapy (+) treatment periods of the study. Individual patients are identified by letters A through J and correspond with the identification letters in Figure 2. Panel B: Optical scanning of the zymograms from panel A, with values reported as densitometric units. Solid bars = placebo; open bars = estrogen. MMP = matrix metalloproteinase.